Der Oncotype DX Brustkrebstest ist der einzige genomische Test, der sowohl für eine sichere Aussage über den zu erwartenden Nutzen einer Chemotherapie als auch über das Rückfallrisiko bei …

In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.

The Oncotype DX Breast Recurrence Score® Test is offered to healthcare professionals by the Genomic Health Inc. centralized laboratory in Redwood City, California, USA.

解 説 1)Oncotype DX Oncotype DXは,ホルマリン固定標本を用いて16 個の腫瘍関連遺伝子と5 個の参照遺伝子から構成される21個の遺伝子をRT-PCR で解析し,0~100 のRecurrence Score(RS)を 算出す …

The Oncotype DX Breast Recurrence Score test can help to make treatment decisions in early stage, oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2 …

El test Oncotype DX identifica a las pacientes que se beneficiarán o no de la quimioterapia adyuvante, proporcionando tres datos: el resultado Recurrence Score, el riesgo de recurrencia a distancia y el …

Oncotype DX test helps identify which women with early-stage, estrogen receptor-positive (ER+) invasive breast cancer are more likely to benefit from adding chemotherapy to their hormonal treatment.

Linee guida per il medico per il test Oncotype DX Breast Recurrence Score®, fornisce informazioni su come ordinare il test, tracciare gli ordini, ricevere i referti dei test e contattare il Servizio Clienti di …

El test Oncotype DX es un test diagnóstico molecular que analiza la biología individual de un tumor canceroso de mama, examinando la actividad de 21 genes en el tejido tumoral. Los resultados del …

The committee concluded that Oncotype DX® was likely to be a cost-effective use of NHS resources when used to help guide adjuvant chemotherapy decision making with postmenopausal women.